O

Opus Genetics, Inc. (IRD)

NCM – Real vaqt narxi. Valyuta: USD

5.18

+0.06 (1.17%)

Yopilishda: May 12, 2026, 4:00 PM EDT

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Barcha huquqlar himoyalangan.

Foydalanish shartlari

O

Opus Genetics, Inc. (IRD)

NCM – Real vaqt narxi. Valyuta: USD

5.18

+0.06 (1.17%)

Yopilishda: May 12, 2026, 4:00 PM EDT

12.05.2026

Opus Genetics, Inc. (IRD) Reports Q1 Loss, Misses Revenue Estimates

Opus Genetics, Inc. (IRD) came out with a quarterly loss of $0.75 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to a loss of $0.32 per share a year ago.

12.05.2026

Opus Genetics Announces Financial Results for First Quarter 2026 and Provides Corporate Update

Opus Genetics Virtual R&D Science Forum Scheduled for Tuesday, June 16, 2026, at 10:00 am ET Upcoming Data Readout for Cohort 1 of OPGx-BEST1 Gene Therapy Study Expected in September 2026 LCA5 Accepted to FDA's Rare Disease Evidence Principles (RDEP) Program and Enrolling Pivotal Trial RDH12, MERTK and RHO Programs Expected to Advance to Clinical Testing in the Next 12 Months Cash Runway into 2029 Expected to Support Multiple Clinical Inflection Points, Potential Product Approvals and Opportunities for Priority Review Vouchers RESEARCH TRIANGLE PARK, N.C., May 12, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the “Company” or “Opus Genetics”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced financial results for the first quarter ended March 31, 2026, and provided a corporate update.

07.05.2026

Opus Genetics Presents Clinical and Preclinical Data at ARVO 2026 Demonstrating Continued Pipeline Advancement in Inherited Retinal Diseases

Six-Month Clinical Data Demonstrate Restoration of Cone-Mediated Vision in Pediatric LCA5 Patients, with Sensitivity Improvements Reaching Normal Ranges Early BEST1 Data Show Visual Acuity Gains and Improved Retinal Structure, Supporting Expansion into a Large IRD Population Preclinical RHO Programs Demonstrate Durable Retinal Preservation and Support Clinical Translation Mutation-Independent AAV Approach Highlights Potential to Address Genetically Diverse Retinal Diseases with a Single Therapy Advancements In Potency Assays and Manufacturing Reinforce Scalability and Regulatory Readiness RESEARCH TRIANGLE PARK, N.C., May 07, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced new clinical and preclinical data from multiple programs presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2026 in Denver, Colorado.

07.05.2026

Opus Genetics Completes Enrollment in Cohort 1 of Phase 1/2 OPGx-BEST1 Gene Therapy Study

Target Enrollment Achieved with the Inclusion of Participants with Both Dominant and Recessive Forms of BEST Disease Baseline Demographics Presented at ARVO Annual Meeting with Summary Audio and Slide Presentation Available on Opus Website Three-Month Topline Results from Cohort 1 Expected in September 2026 RESEARCH TRIANGLE PARK, N.C., May 07, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced the completion of enrollment in Cohort 1 of its ongoing Phase 1/2 study of OPGx-BEST1 gene therapy.

04.05.2026

Opus Genetics Announces FDA Acceptance of OPGx-LCA5 into Rare Disease Evidence Principles (RDEP) Program

RESEARCH TRIANGLE PARK, N.C., May 04, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced that its investigational LCA5 gene therapy program, OPGx-LCA5, has been accepted into the U.S. Food and Drug Administration's (FDA) Rare Disease Evidence Principles (RDEP) program.

27.04.2026

Opus Genetics to Participate in Leading Medical Conferences in May 2026

RESEARCH TRIANGLE PARK, N.C., April 27, 2026 (GLOBE NEWSWIRE) -- Opus Genetics (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced that members of its leadership team will participate in several leading ophthalmology and industry conferences.

$Opus Genetics Announces Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting$

10.04.2026

Opus Genetics Announces Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting

RESEARCH TRIANGLE PARK, N.C., April 10, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced that three abstracts will be presented at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting in Washington, D.C.

Videolar

No Data

There is no data to display

Press-relizlar

12.05.2026

Opus Genetics Announces Financial Results for First Quarter 2026 and Provides Corporate Update

Opus Genetics Virtual R&D Science Forum Scheduled for Tuesday, June 16, 2026, at 10:00 am ET Upcoming Data Readout for Cohort 1 of OPGx-BEST1 Gene Therapy Study Expected in September 2026 LCA5 Accepted to FDA's Rare Disease Evidence Principles (RDEP) Program and Enrolling Pivotal Trial RDH12, MERTK and RHO Programs Expected to Advance to Clinical Testing in the Next 12 Months Cash Runway into 2029 Expected to Support Multiple Clinical Inflection Points, Potential Product Approvals and Opportunities for Priority Review Vouchers RESEARCH TRIANGLE PARK, N.C., May 12, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the “Company” or “Opus Genetics”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced financial results for the first quarter ended March 31, 2026, and provided a corporate update.

07.05.2026

Opus Genetics Presents Clinical and Preclinical Data at ARVO 2026 Demonstrating Continued Pipeline Advancement in Inherited Retinal Diseases

Six-Month Clinical Data Demonstrate Restoration of Cone-Mediated Vision in Pediatric LCA5 Patients, with Sensitivity Improvements Reaching Normal Ranges Early BEST1 Data Show Visual Acuity Gains and Improved Retinal Structure, Supporting Expansion into a Large IRD Population Preclinical RHO Programs Demonstrate Durable Retinal Preservation and Support Clinical Translation Mutation-Independent AAV Approach Highlights Potential to Address Genetically Diverse Retinal Diseases with a Single Therapy Advancements In Potency Assays and Manufacturing Reinforce Scalability and Regulatory Readiness RESEARCH TRIANGLE PARK, N.C., May 07, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced new clinical and preclinical data from multiple programs presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2026 in Denver, Colorado.

07.05.2026

Opus Genetics Completes Enrollment in Cohort 1 of Phase 1/2 OPGx-BEST1 Gene Therapy Study

Target Enrollment Achieved with the Inclusion of Participants with Both Dominant and Recessive Forms of BEST Disease Baseline Demographics Presented at ARVO Annual Meeting with Summary Audio and Slide Presentation Available on Opus Website Three-Month Topline Results from Cohort 1 Expected in September 2026 RESEARCH TRIANGLE PARK, N.C., May 07, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced the completion of enrollment in Cohort 1 of its ongoing Phase 1/2 study of OPGx-BEST1 gene therapy.

04.05.2026

Opus Genetics Announces FDA Acceptance of OPGx-LCA5 into Rare Disease Evidence Principles (RDEP) Program

RESEARCH TRIANGLE PARK, N.C., May 04, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced that its investigational LCA5 gene therapy program, OPGx-LCA5, has been accepted into the U.S. Food and Drug Administration's (FDA) Rare Disease Evidence Principles (RDEP) program.

Search stocks

Opus Genetics, Inc. (IRD)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Opus Genetics, Inc. (IRD)

Opus Genetics, Inc. (IRD) Reports Q1 Loss, Misses Revenue Estimates

Opus Genetics Announces Financial Results for First Quarter 2026 and Provides Corporate Update

Opus Genetics Presents Clinical and Preclinical Data at ARVO 2026 Demonstrating Continued Pipeline Advancement in Inherited Retinal Diseases

Opus Genetics Completes Enrollment in Cohort 1 of Phase 1/2 OPGx-BEST1 Gene Therapy Study

Opus Genetics Announces FDA Acceptance of OPGx-LCA5 into Rare Disease Evidence Principles (RDEP) Program

Opus Genetics to Participate in Leading Medical Conferences in May 2026

Opus Genetics Announces Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting

Videolar

No Data

Press-relizlar

Opus Genetics Announces Financial Results for First Quarter 2026 and Provides Corporate Update

Opus Genetics Presents Clinical and Preclinical Data at ARVO 2026 Demonstrating Continued Pipeline Advancement in Inherited Retinal Diseases

Opus Genetics Completes Enrollment in Cohort 1 of Phase 1/2 OPGx-BEST1 Gene Therapy Study

Opus Genetics Announces FDA Acceptance of OPGx-LCA5 into Rare Disease Evidence Principles (RDEP) Program